Skip to main content
Explore URMC

CLUN20055 / EA5181 / Arpan Patel, MD

Research Question:
How well does durvalumab, an antibody, work when added to chemoradiation for treating patients with lung cancer?

Basic Study Information

This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if adding durvalumab to standard chemoradiation followed by additional durvalumab can extend patients life and/or prevent the tumor from coming back compared to the usual approach of chemoradiation alone followed by durvalumab.

Location: University of Rochester Medical Center
Study Reference #: CLUN20055

Lead Researcher (Principal Investigator)

Lead Researcher:  Arpan Patel

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search